Compare · HSDT vs NPCE
HSDT vs NPCE
Side-by-side comparison of Solana Company (HSDT) and Neuropace Inc. (NPCE): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both companies sit in the Health Care sector. HSDT focuses on Biotechnology: Electromedical & Electrotherapeutic Apparatus, while NPCE focuses on Medical/Dental Instruments.
- NPCE is the larger of the two at $260.5M, about 2.4x HSDT ($108.8M).
- NPCE has been more active in the news (7 items in the past 4 weeks vs 5 for HSDT).
- NPCE has more recent analyst coverage (20 ratings vs 3 for HSDT).
- Company
- Solana Company
- Neuropace Inc.
- Price
- -
- -
- Market cap
- $108.8M
- $260.5M
- 1M return
- -
- -3.95%
- 1Y return
- -
- -6.16%
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2021
- News (4w)
- 5
- 7
- Recent ratings
- 3
- 20
Solana Company
Helius Medical Technologies, Inc., a neurotechnology company, focuses on developing, licensing, and acquiring non-invasive technologies for the treatment of symptoms caused by neurological disease or trauma. Its product, Portable Neuromodulation Stimulator (PoNS), is a non-implantable investigational medical device intended for use as a short term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury, as well as to be used in conjunction with supervised therapeutic exercise. The company is headquartered in Newtown, Pennsylvania.
Neuropace Inc.
NeuroPace, Inc. operates as a medical device company in the United States. The company develops and sells RNS system, a brain-responsive neuromodulation system for treating medically refractory focal epilepsy by delivering personalized real-time treatment at the seizure source. Its RNS system also records continuous brain activity data and enables clinicians to monitor patients in person and remotely. The company sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.
Latest HSDT
- SEC Form 10-Q filed by Solana Company
- Solana Company filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Solana Company Reports Third Quarter 2026 Financial Results
- Solana Company to Release Third Quarter 2026 Operating Results on November 11, 2026
- Solana Company Selected as a Strategic Enterprise by the Hong Kong SAR Government
- SEC Form 424B5 filed by Solana Company
- Solana Company filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Solana Company (NASDAQ: HSDT) Announces Pricing of $15 Million Registered Direct Offering with a Global Institutional Investor
- SEC Form 4 filed by Officer Tjandrasuwita Agustina Gani
- Solana Company Announces Positions and Votes on first Solana Governance Proposals
Latest NPCE
- NeuroPace downgraded by Wells Fargo with a new price target
- NeuroPace downgraded by Leerink Partners with a new price target
- NeuroPace downgraded by Analyst with a new price target
- SEC Form 10-Q filed by Neuropace Inc.
- Neuropace Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- NeuroPace Reports Third Quarter 2026 Financial Results and Provides Revised Full Year Guidance
- NeuroPace to Report Third Quarter 2026 Financial Results on November 12, 2026
- CHIEF MEDICAL OFFICER Morrell Martha covered exercise/tax liability with 335 shares, decreasing direct ownership by 0.65% to 51,357 units (SEC Form 4) (for withholding tax)
- Chief Financial Officer Williams Patrick F. covered exercise/tax liability with 1,162 shares, decreasing direct ownership by 2% to 67,508 units (SEC Form 4) (tax liability)
- KeyBanc Capital Markets initiated coverage on NeuroPace with a new price target